James Nam, PharmD

Most Recent Articles by James Nam, PharmD

Intensified Reduced-Intensity Conditioning May Improve Outcomes in CBT

Intensified Reduced-Intensity Conditioning May Improve Outcomes in CBT

By

Researchers compared survival outcomes of thiotepa-based intensified RIC vs standard RIC among patients undergoing cord-blood transplantation (CBT).

False-Positive Cancer Screening Results May Increase Likelihood of Future Screenings

False-Positive Cancer Screening Results May Increase Likelihood of Future Screenings

By

A logistic regression analysis determined the effect receiving a false-positive result had on future participation in cancer screenings.

Chronic Opioid Use Observed in More Than 50% of Oropharynx Cancer Cases

Chronic Opioid Use Observed in More Than 50% of Oropharynx Cancer Cases

By

Results of a retrospective review assessing the prevalence of chronic opioid use among patients with oropharynx cancer after surgery was presented at the 2018 American Head & Neck Society Annual Meeting.

Elderly Patients Are Underrepresented in Trials For Soft Tissue Sarcoma

Elderly Patients Are Underrepresented in Trials For Soft Tissue Sarcoma

By

With median age of participants in clinical trials for soft-tissue sarcoma younger than most patients who develop the disease, these researchers sought to determine the prevalence of including persons older than 65 in clinical trials and the efficacy of first-line chemotherapy for STS in older patients.

Combination Effective as First-Line Therapy in Advanced ER-Positive HER2-Negative Breast Cancer

Combination Effective as First-Line Therapy in Advanced ER-Positive HER2-Negative Breast Cancer

By

In this open label phase 2 BOLERO-4 study, researchers evaluated the effect of everolimus plus endocrine therapy on progression-free survival.

More Articles by James Nam, PharmD

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs